SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$353M
Q4 2024
Positions
67
Filings on Record
25
2019–present window
Filed
Feb 13, 2025
original filing

Summary

Altium Capital Management LLC reported $353M in U.S.-listed holdings across 67 positions for Q4 2024.

Its largest position, ADMA, represents 6.8% of the portfolio.

Compared with Q3 2024, the fund opened 20 new positions and exited 34.

Portfolio Metrics

Turnover
+32.0%
vs prior filed quarter
Top-10 Concentration
+40.1%
share of reported value
Largest Position
+6.8%
Adma Biologics
New / Exited
20 / 34
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $268MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 94.1%ADR: 3.4%Other: 2.5%
  • Common Stock · 94.1% · $332M
  • ADR · 3.4% · $12M
  • Other · 2.5% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRRKSCHOLAR ROCK HLDG CORPNEW+300.0K300.0K+$13M$13M
ARGXARGENX SENEW+10.0K10.0K+$6M$6M
RMDRESMED INCNEW+26.0K26.0K+$6M$6M
EXKEXACT SCIENCES CORPNEW+100.0K100.0K+$6M$6M
CMPSCOMPASS PATHWAYS PLCNEW+1.42M1.42M+$5M$5M
SNDXSYNDAX PHARMACEUTICALS INCNEW+370.0K370.0K+$5M$5M
AVRANTERIS TECHNOLOGIES GLOBALNEW+737.0K737.0K+$4M$4M
PROFPROFOUND MED CORPNEW+485.0K485.0K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

61 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ADMAADMA BIOLOGICS INChistory →COM6.79%$24M1.40M
2VERAVERA THERAPEUTICS INChistory →CL A5.18%$18M432.0K
3SRPTSAREPTA THERAPEUTICS INChistory →COM4.38%$15M127.0K
4ZVRAZEVRA THERAPEUTICS INChistory →COM NEW4.38%$15M1.85M
5ESTAESTABLISHMENT LABS HLDGS INChistory →COM3.99%$14M305.0K
6EWEDWARDS LIFESCIENCES CORPhistory →COM3.46%$12M165.0K
7XENEXENON PHARMACEUTICALS INChistory →COM3.20%$11M288.0K
8SOLENO THERAPEUTICS INCCOM3.19%$11M250.0K
9CAPRCAPRICOR THERAPEUTICS INChistory →COM NEW2.79%$10M714.0K
10RXSTRXSIGHT INChistory →COM2.78%$10M285.0K
11MMSIMERIT MED SYS INChistory →COM2.74%$10M100.0K
12BHVNBIOHAVEN LTDhistory →COM2.65%$9M250.0K
13INSMINSMED INChistory →COM PAR $.012.58%$9M132.0K
14RZLTREZOLUTE INChistory →COM NEW2.35%$8M1.69M
15EOLSEVOLUS INChistory →COM2.14%$8M685.0K
16INTRA-CELLULAR THERAPIES INCCOM1.78%$6M75.0K
17ARGXARGENX SEhistory →SPONSORED ADR1.74%$6M10.0K
18GKOSGLAUKOS CORPhistory →COM1.70%$6M40.0K
19RMDRESMED INChistory →COM1.69%$6M26.0K
20VKTXVIKING THERAPEUTICS INChistory →COM1.67%$6M146.0K
21EXKEXACT SCIENCES CORPhistory →COM1.59%$6M100.0K
22LUNGPULMONX CORPhistory →COM1.57%$6M815.0K
23CMPSCOMPASS PATHWAYS PLChistory →SPONSORED ADS1.53%$5M1.42M
24CN2CATALYST PHARMACEUTICALS INChistory →COM1.51%$5M255.0K
25CTNMCONTINEUM THERAPEUTICS INChistory →CL A1.39%$5M334.0K
26SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.39%$5M370.0K
27SVRASAVARA INChistory →COM1.37%$5M1.58M
28AVADEL PHARMACEUTICALS PLCCOM SHS1.35%$5M452.5K
29CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW1.29%$5M385.0K
30ARWRARROWHEAD PHARMACEUTICALS INhistory →COM1.23%$4M230.3K
31AVRANTERIS TECHNOLOGIES GLOBALhistory →COM1.17%$4M737.0K
32PROFPROFOUND MED CORPhistory →COM NEW1.03%$4M485.0K
33XTNTXTANT MED HLDGS INCCOM NEW0.93%$3M7.42M
34SKYESKYE BIOSCIENCE INCCOM NEW0.91%$3M1.14M
35ORICORIC PHARMACEUTICALS INCCOM0.81%$3M355.0K
36TGTXTG THERAPEUTICS INCCOM0.81%$3M95.0K
37NEKTAR THERAPEUTICSCOM0.79%$3M3.00M
38KROSKEROS THERAPEUTICS INCCOM0.79%$3M175.0K
39IBRXIMMUNITYBIO INCCOM0.77%$3M1.06M
40LXEOLEXEO THERAPEUTICS INCCOM0.76%$3M405.0K
41TERNS PHARMACEUTICALS INCCOM0.75%$3M475.0K
42RVMDREVOLUTION MEDICINES INCCOM0.74%$3M60.0K
43ESSA PHARMA INCCOM NEW0.73%$3M1.43M
44ATECALPHATEC HLDGS INCCOM NEW0.69%$2M264.6K
45LRMRLARIMAR THERAPEUTICS INCCOM0.55%$2M505.0K
46OKURONKURE THERAPEUTICS INCCOM CL A0.53%$2M218.4K
47ACOGALPHA COGNITION INCCOM NEW0.46%$2M275.0K
48PROQR THRAPEUTICS N VSHS EURO0.43%$2M575.0K
49VERU INCCOM0.37%$1M2.03M
50UNICYCIVE THERAPEUTICS INCCOM0.33%$1M1.47M
51ENVVENO MEDICAL CORPORATIONCOM0.27%$936,200310.0K
52BCYCBICYCLE THERAPEUTICS PLCSPONSORED ADS0.16%$564,92840.4K
53PROMIS NEUROSCIENCES INCCOM NEW0.16%$551,046581.4K
54FULCFULCRUM THERAPEUTICS INCCOM0.15%$525,516111.8K
55KARYOPHARM THERAPEUTICS INCCOM0.14%$500,462740.0K
56CTMXCYTOMX THERAPEUTICS INCCOM0.14%$481,516467.5K
57CATXPERSPECTIVE THERAPEUTICS INCCOM NEW0.08%$294,19592.2K
58BETTER CHOICE CO INCCOM NEW0.08%$278,379118.5K
59ANABANAPTYSBIO INCCOM0.07%$242,63618.3K
60QUOIN PHARMACEUTICALS LTDSPONSORED ADS0.05%$183,659282.2K
61CELLECTAR BIOSCIENCES INCCOM NEW0.02%$64,285215.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$268M95May 5, 2021RESTATEMENTchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.